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Purpose: A single-entity, once-daily, extended-release
formulation of hydrocodone bitartrate (HYD) has been
developed for the management of moderate to severe
chronic pain. Hydrocodone undergoes cytochrome P-450
(CYP)-mediated metabolism involving the CYP3A4 and
CYP2D6 isozymes. CYP3A4 yields norhydrocodone, a
major inactive metabolite, whereas CYP2D6 yields hy-
dromorphone, a minor active metabolite. This study
examined the inﬂuence of the coadministration of parox-
etine, a strong selective CYP2D6 inhibitor, on the
pharmacokinetic properties of hydrocodone (and hydro-
morphone) in healthy adults.
Methods: In this randomized, double-blind, 2-
period, 2-treatment crossover study, 24 healthy sub-
jects received paroxetine 20 mg or placebo once daily
for 12 days and an HYD 20-mg tablet on day 10 of
each period.
Findings: Hydrocodone mean Cmax and t½ and
median Tmax values were similar with paroxetine or
placebo coadministration (16.8 vs 15.9 ng/mL, 8.5 vs
8.4 hours, and 18.0 vs 18.0 hours, respectively), as
were mean AUC0–t and AUC0–1 values (342.9 vs
325.3 ng  h/mL and 346.3 vs 328.5 ng  h/mL). The
90% CIs of the geometric mean ratios of the hydro-
codone AUC and Cmax values were fully within the
predetermined range of 80% to 125%, suggesting that
there was no effect of multiple doses of paroxetine on
systemic exposure to hydrocodone. Mean hydromor-
phone AUC0–t and Cmax values were decreased with
paroxetine versus placebo (0.64 vs 3.8 ng  h/mL and
0.06 vs 0.19 ng/mL), whereas Tmax values remained
similar (18.0 vs 16.1 hours, respectively). The
mean hydromorphone AUC0–1 value could not be2286calculated. Both regimens were well tolerated; after
HYD administration, the numbers of adverse events
were similar between the 2 treatment regimens, and all
adverse events were mild.
Implications: In this study, the coadministration of
single-dose HYD with paroxetine at steady state did
not alter systemic exposure to hydrocodone, suggest-
ing that HYD can be coadministered with CYP2D6
inhibitors at therapeutic doses, without dosage mod-
iﬁcation. (Clin Ther. 2015;37:2286–2296) & 2015
The Authors. Published by Elsevier HS Journals, Inc.
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Hydrocodone is a semisynthetic opioid that produces
analgesic activity primarily via μ-receptor agonism. The
pharmacologic and pharmacokinetic (PK) properties of
hydrocodone are characteristic of many opioid analge-
sics, and the relative analgesic potency of hydrocodone is
considered to be approximately equivalent to that of
oxycodone and twice that of oral morphine.1,2Volume 37 Number 10
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Figure 1. Metabolism of hydrocodone.
R.P. Kapil et al.In the United States, hydrocodone is often combined
with a nonopioid drug, such as acetaminophen or
ibuprofen. Hydrocodone/acetaminophen combination
products are the most commonly prescribed drugs in
the United States, with an estimated 129.2 million
prescriptions in 2013.3 In October 2013, the use of a
single-entity, twice-daily, extended-release formulation
of hydrocodone bitartrate was approved by the US
Food and Drug Administration.4 In November 2014,
a single-entity, once-daily, extended-release tablet for-
mulation of hydrocodone bitartrate (HYD)* was
approved by the US Food and Drug Administration
for the management of pain severe enough to require
daily, around-the-clock, long-term opioid treatment
and for which alternative treatment options are inad-
equate.5 HYD, an extended-release formulation, is
available in multiple tablet strengths (20–120 mg)
and does not contain a nonopioid component, permit-
ting the treatment of chronic pain that requires higher
total daily opioid doses. Additionally, HYD incorpo-
rates a proprietary extended-release technology that
provides physicochemical attributes intended to impart
abuse-deterrent properties.
Hydrocodone undergoes extensive cytochrome
P-450 (CYP)-mediated oxidative metabolism involv-
ing CYP3A4-mediated N-demethylation, yielding no-
rhydrocodone (major inactive metabolite; 40% of*Trademark: Hysingla ERs (Purdue Pharma L.P., Stamford,
Connecticut).
October 2015circulating parent drug) and CYP2D6-mediated
O-demethylation, yielding hydromorphone (minor
active metabolite; up to 3% of circulating parent
drug) (Figure 1).5,6 When hydrocodone was
administered as a single oral dose of 15 mg, of the
overall dose, urinary excretion values of the parent drug
and its metabolites were as follows: hydrocodone, 11%;
hydromorphone, 3.5%; norhydrocodone, 5.2%; and
other metabolites (eg, 6-α/β-hydroxy metabolites),
o3%. The mean total recovery values of
hydrocodone and its metabolites were 25.7% and
13.2%, respectively.6 Other CYP isoforms, including
2B6, 2C9, 2C19, and 2E1, are minor contributors to
hydrocodone metabolism.7
The effects of the concurrent administration of
CYP2D6 inhibitors with HYD on the tolerability of
HYD have not been established. Paroxetine, a selec-
tive serotonin reuptake inhibitor used for treating
depression in children and adults,8 is a strong
selective CYP2D6 inhibitor.9–11
Although the effects of CYP2D6 inhibition on
hydrocodone exposure are not expected to be clin-
ically meaningful, this hypothesis remains to be con-
ﬁrmed, considering the prevalence of multidrug
exposure among patients taking opioids.12 This
study examined the inﬂuence of CYP2D6 inhibition
by paroxetine at steady state on the PK properties of
hydrocodone and its minor active metabolite
hydromorphone after the administration of a single
dose of oral HYD in healthy adults.2287
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Figure 2. Study design. aParoxetine (or placebo) 20 mg orally once daily in the morning on days 1 to 12
(period 1) or days 14 to 25 (period 2). CI ¼ check-in to clinic; R ¼ randomization to treatment
sequences (period 1 only).
Clinical TherapeuticsSUBJECTS AND METHODS
Study Design
This single-center (PPD Phase I Clinic, Austin, TX),
randomized, double-blind, 2-period, 2-treatment,
2-way crossover, drug–drug interaction study eval-
uated the effects of CYP2D6 inhibition on the PK
properties of hydrocodone after the oral administra-
tion of HYD in healthy adults (Figure 2). The primary
objective was to evaluate the PK properties of hydro-
codone in the presence and absence of paroxetine. The
secondary objective was to assess the tolerability of
the concurrent administration of HYD and paroxetine
in healthy adults.
Subjects were randomly assigned, in a 1:1 ratio, to
receive either HYD þ paroxetine (A) or HYD þ
placebo (B) in period 1 (days 1–12), followed by
crossover to the alternate treatment in period 2 (days
14–25). Paroxetine 20-mg tablets†,8 or placebo tablets
were administered once daily in the morning after an
overnight fast, on every day of each period. A single
HYD 20-mg tablet was administered once in each
period (day 10 or 23) after an overnight fast. To avoid
carryover effects, adequate study medication washout
periods were built into the study design, based on each
drug’s terminal half-life. In subjects assigned to receive
paroxetine in period 1, there were 10 days between
the administration of the last paroxetine dose in
period 1 (day 12) and the administration of HYD
with paroxetine-matched placebo in period 2 (day 23).
In subjects assigned to receive paroxetine-matched†Trademark: Paxils (GlaxoSmithKline, Research Triangle Park,
North Carolina).
2288placebo in period 1, there were 4 days between
HYD dosing in period 1 (day 10) and the admin-
istration of the ﬁrst dose of paroxetine in period 2
(day 14). Subjects entered the study unit and were
randomized before paroxetine dosing on day 1 and
remained conﬁned to the study unit until the end of
period 2.
The protocol and informed-consent form were
reviewed and approved by the IntegReview institu-
tional review board (Austin, Texas) before subjects
were screened for entry into the study. The study was
conducted in compliance with the International Con-
ference on Harmonisation E6 Good Clinical Practice
guideline and the US Code of Federal Regulations
guideline. All subjects provided written informed
consent.
Sample Size
No formal sample size calculations were per-
formed; it was expected that the randomization of
24 subjects would provide sufﬁcient treatment
replications.
Study Population
Healthy subjects 18 to 50 years of age could enroll if
they had a body weight ranging from 50 to 100 kg and
a body mass index ranging from 18 to 30 kg/m2; were
willing to eat the food supplied during the study, refrain
from strenuous exercise through the end-of-study visit,
and avoid beginning a new exercise program or
participating in any unusually strenuous physical
exertion; and had no signiﬁcant abnormal ﬁndings
on medical history taking, physical examination, clinicalVolume 37 Number 10
R.P. Kapil et al.laboratory analysis, vital sign measurement, and
12-lead ECG. In addition, female subjects of child-
bearing age who were not pregnant or breastfeeding
were required to use an adequate and reliable method
of contraception (ie, barrier with additional spermicidal
foam or jelly, intrauterine device, or hormonal contra-
ception), and female subjects who were postmenopausal
for at least 1 year were required to have an elevated
serum follicle-stimulating hormone level.
Subjects were excluded from the study for the
following reasons: current or recent (within 5 years)
history of drug or alcohol abuse; history or any
current conditions that may have interfered with drug
absorption, distribution, metabolism, or excretion; use
of an opioid-containing medication in the 30 days
preceding the administration of the ﬁrst dose of study
medication; known sensitivity to hydrocodone, parox-
etine, or related compounds; history of depression or
other history with an increased potential for suicide;
history of frequent nausea or emesis regardless of
etiology; history of seizures or head trauma with
sequelae; participation in a clinical study in the 30
days preceding the administration of the ﬁrst dose of
study medication; any signiﬁcant illness in the 30 days
preceding the administration of the ﬁrst dose of study
medication; any personal or family history of a
prolonged QT interval or cardiac rhythm disorders;
and/or abnormal cardiac conditions (corrected QT
interval Z450 ms at screening or corrected QT
interval Z480 ms or greater during the treatment
period).
Subjects were also excluded if they refused to
abstain from food intake for 10 hours before dosing
and 4 hours after dosing of HYD with paroxetine or
placebo; caffeine- or xanthine-containing beverages
entirely during conﬁnement; alcoholic beverages for
7 days preceding the administration of the ﬁrst dose of
study medication and throughout the study; over-the-
counter or prescription medications, including thyroid
hormonal therapy (hormonal contraception and
hormone-replacement therapy in the form of estrogen
with or without progestin was allowed), vitamins, or
dietary/herbal/mineral supplements for 7 days preced-
ing the administration of the ﬁrst dose of study
medication and throughout the study; and/or any
food or beverage containing grapefruit or grapefruit
juice, apple or orange juice, vegetables from the
mustard green family, or charbroiled meats for 7 days
preceding the administration of the ﬁrst dose of studyOctober 2015medication and throughout the study. Furthermore,
subjects were excluded if they had a history of
smoking or use of nicotine products in the 45 days
preceding the administration of the ﬁrst dose of study
medication or a positive urine cotinine test; donated
blood or blood products in the 30 days preceding the
administration of the ﬁrst dose of study medication or
any time throughout the study, except as required by
the study; a positive result on a urine drug screen or
alcohol screen, hepatitis B surface antigen screen, or
hepatitis C antibody screen; presence of Gilbert’s
syndrome or any known hepatobiliary abnormalities;
and/or any reason(s) for which the investigator
deemed the subject unsuitable for inclusion in the
study.Sample Collection
Blood samples used for the quantiﬁcation of the
plasma concentration of hydrocodone were collected
predose on days 10 and 23 and at 0.5, 1, 2.5, 4, 6, 8,
10, 12, 14, 16, 18, 24, 30, 36, 48, 72, and 80 hours
after HYD dosing. Blood samples used for the quanti-
ﬁcation of the plasma concentration of paroxetine
were collected before HYD dosing on days 10
and 23.Bioanalytical Methods
Human plasma (K2EDTA as an anticoagulant)
was analyzed for hydrocodone, hydromorphone,
and norhydrocodone and the internal standards
(hydrocodone-d3, hydromorphone-d6 and norhydro-
codone-d3.HCl) using high-performance liquid
chromatography with column switching and tandem
mass spectrometry detection using positive ion electro-
spray. The assay was found to be linear from 0.1 to
100 ng/mL for hydrocodone and norhydrocodone,
and from 0.05 to 50 ng/mL for hydromorphone,
based on a 100-mL sample.Pharmacokinetic Assessments
In each subject, the following PK parameters were
calculated based on the plasma concentration of
hydrocodone: AUC0–t, calculated by the linear trape-
zoidal method; AUC0–1, calculated as AUC0–t þ Ct/λz,
where Ct was the last measurable plasma concentration
and λz was the apparent terminal-phase rate constant;
Cmax; Tmax; and t½, where t½ was the apparent
terminal-phase half-life.2289
Clinical TherapeuticsTolerability Assessments
Tolerability was assessed based on the recording of
adverse events (AEs), assessed using clinical laboratory
tests (biochemistry, hematology, and urinalysis), vital
sign measurements, oxygen saturation measurements,
ECG results, and ﬁndings determined on physical
examination. All AEs were coded using the terms from
the Medical Dictionary for Regulatory Activities ver-
sion 15.0 and were assessed by the investigator for
severity and relatedness to study medication.
At the end of the study (80 hours postdose, end of
period 2) or early discontinuation, the following were
conducted: routine physical examination, vital sign
assessment, blood and urine collection for laboratory
tests, serum pregnancy test for women, and ECG.
Concurrent medications and AEs were recorded. Any
case of emesis was documented by the study staff.
Seven to 10 days after the administration of the ﬁnal
dose of study medication, subjects were contacted by
phone to determine the presence of any AEs.N = 54Pharmacokinetic Assessments
PK properties were calculated, based on the plasma
concentration of hydrocodone, by noncompartmental
PK analysis (model-independent approach) using
Phoenix WinNonlin version 6.2.1. (Pharsight Corpo-
ration, St. Louis, Missouri). Plasma concentrations
less than the lower limit of quantiﬁcation were set to 0
in the concentration summary, plots, and PK param-
eter calculations. Concentrations below the lower
limit of quantiﬁcation at the end of the PK proﬁle
were included in the calculations.Subjects screened
(enrolled)
n = 24
Subjects
randomized
n = 30
Screen
failures
 
n  = 24Period 1
n= 24Period 2
n = 1
Discontinued
study
(subject’s choice)
n = 23
Subjects
completed
Figure 3. Subject disposition.Statistical Analysis
The PK properties with the 2 treatment regimens
were summarized using descriptive statistics, which
included sample sizes, means (SD), %CVs, medians
(range), and geometric means.
Statistical analysis of the effects of paroxetine on
hydrocodone and hydromorphone PK properties was
performed using an ANOVA model on the natural
logarithms (ln) of the parameters, with treatment,
sequence, and period as ﬁxed effects and subject within
sequence as a random effect. The analysis was per-
formed using the following linear mixed model:
Parameter¼SequenceþSubject sequenceð Þ
þPeriodþTreatmentþRandom errorh ð1Þ2290For hydrocodone and hydromorphone, a compar-
ison of the ln-transformed AUC0–t, AUC0–1, and
Cmax values (calculated when possible) in the presence
and absence of paroxetine was performed. Geometric
mean ratios (90% CIs) of the AUC0–t, AUC0–1, and
Cmax values were calculated when possible.
RESULTS
Subjects
Among the 54 healthy subjects screened, 24 sub-
jects were randomized (Figure 3). Twenty-three sub-
jects completed the study; 1 subject discontinued
during period 2 due to personal choice. The full
analysis population included 24 subjects, as did the
per-protocol population. The baseline demographic
and clinical characteristics of the per-protocol popu-
lation are presented in Table I. Overall, the mean age
of the subjects was 36.0 years, subjects were
predominantly white (63%), and equal numbers of
men and women were in the study (50% each). The
baseline characteristics of the 2 treatment groups were
similar (Table I).
Pharmacokinetic Results
The descriptive statistics of the PK properties of
hydrocodone and hydromorphone are summarized in
Table II. The mean Cmax and t½ and median Tmax
values of hydrocodone were similar in the presence
and absence of paroxetine (16.8 vs 15.9 ng/mL, 8.5 vsVolume 37 Number 10
Table I. Baseline demographic and clinical characteristics (per-protocol population).
Characteristic AB (n ¼ 12) BA (n ¼ 12) All Patients (N ¼ 24)
Age
Mean (SD), y 35.7 (8.80) 36.3 (7.79) 36.0 (8.14)
Group, no. (%)
18–o40 y 6 (50) 7 (58) 13 (54)
40–50 y 6 (50) 5 (42) 11 (46)
Male, n (%) 6 (50) 6 (50) 12 (50)
Race, no. (%)
White 8 (67) 7 (58) 15 (63)
Black or African American 3 (25) 4 (33) 7 (29)
Native American or Native Alaskan 1 (8) 0 1 (4)
Other 0 1 (8) 1 (4)
Ethnicity, no. (%)
Hispanic or Latino 6 (50) 4 (33) 10 (42)
Non-Hispanic or Non-Latino 6 (50) 8 (67) 14 (58)
Height, mean (SD), cm 169.2 (10.20) 167.8 (7.57) 168.5 (8.81)
Weight, mean (SD), kg 76.9 (11.63) 71.6 (12.28) 74.3 (12.02)
Body mass index, mean (SD), kg/m2 26.8 (2.86) 25.3 (2.66) 26.1 (2.81)
A ¼ hydrocodone bitartrate 20 mg þ paroxetine 20 mg; B ¼ hydrocodone bitartrate 20 mg þ placebo.
Table II. Pharmacokinetic properties of hydrocodone (full analysis population).* Data are given as mean
(SD) unless otherwise noted.
Parameter
Hydrocodone Bitartrate
20 mg þ Paroxetine (n ¼ 23)
Hydrocodone Bitartrate
20 mg þ Placebo (n ¼ 24)
Hydrocodone
AUC0–t, ng  h/mL 342.9 (79.31) 325.3 (84.99)
AUC0–1, ng  h/mL 346.3 (79.34) 328.5 (85.31)
Cmax, ng/mL 16.8 (4.75) 15.9 (4.83)
Tmax, median (range), h 18.0 (12.2–24.0) 18.0 (10.0–24.0)
t½, h 8.5 (2.48) 8.4 (3.39)
Hydromorphone
AUC0–t, ng  h/mL 0.64 (0.748) 3.8 (2.51)
AUC0–1, ng  h/mL NA NA
Cmax, ng/mL 0.06 (0.052) 0.19 (0.119)
Tmax, median (range), h 18.0 (12.0–24.0) 16.1 (12.0–24.0)
t½, h NA NA
NA ¼ not available.
*For hydromorphone, the majority of subjects had a lower limit of quantiﬁcation (LLOQ) (0.05 ng/mL) or near-LLOQ across
the concentration–time proﬁle. Therefore, these results were not reported.
R.P. Kapil et al.
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Clinical Therapeutics8.4 hours, and 18.0 vs 18.0 hours, respectively).
Furthermore, the mean AUC0–t and AUC0–1 values
were similar in the presence and absence of paroxetine
(342.9 vs 325.3 ng  h/mL and 346.3 vs 328.5 ng  h/mL).
For hydromorphone, the administration of paroxetine
decreased the mean AUC0–t value (0.64 vs 3.8 ng  h/mL)
and the mean Cmax value (0.06 vs 0.19 ng/mL) relative
to placebo. The mean hydrocodone Cmax and AUC
values in the presence and absence of paroxetine are
presented in Figure 4.
The mean plasma concentration–time proﬁles of
hydrocodone and hydromorphone were similar re-
gardless of the presence of paroxetine (Figure 5). The
geometric least squares mean ratios ([HYD with
paroxetine]/[HYD without paroxetine]) and 90%
CIs of the hydrocodone AUC and Cmax values were
105.9% (97.7–114.6) and 106.0% (92.7–121.2),
respectively, which were within the predetermined
range of 80% to 125%, suggesting that steady-state
paroxetine did not affect systemic hydrocodone ex-
posure when coadministered with HYD (Table III).0
5
10
15
20
25
Hydrocodone
M
ea
n 
C
m
ax
 (
ng
/m
L)
 
Hydrocodone bitartrate
20 mg + paroxetine
Hydrocodone bitartrate
20 mg + placebo
0
0
0
0
0
0
0
0
0
M
ea
n 
C
m
ax
 (
ng
/m
L)
 
0
50
100
150
200
250
300
350
400
450
M
ea
n 
A
U
C
 (
ng
·h
/m
L)
 
Hydrocodone
Hydrocodone bitartrate
20 mg + paroxetine
Hydrocodone bitartrate
20 mg + placebo
AUCt AUCinf
M
ea
n 
A
U
C
 (
hr
·n
g/
m
L)
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2292Tolerability
A summary of AEs is presented in Table IV. All
AEs were mild in intensity and resolved by the end of
the study. The numbers of post-HYD treatment-
related AEs were similar between the 2 treatment
regimens (ie, HYD þ paroxetine vs HYD þ placebo).
No deaths, serious AEs, or early discontinuations due
to AEs were reported. In addition, there were no
clinically signiﬁcant changes in ECG results, clinical
laboratory values, vital sign measurements, or oxygen
saturation measurements for either treatment (parox-
etine vs placebo) before or after HYD administration.
DISCUSSION
The effects of the concurrent administration of HYD
and a CYP2D6 inhibitor on the tolerability and PK
properties of hydrocodone have not been established
in the clinic. This study examined the inﬂuence of
CYP2D6 inhibition by paroxetine (a strong CYP2D6
inhibitor)10,11 at steady state on the PK properties
of hydrocodone and its minor active metabolite.00
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R.P. Kapil et al.hydromorphone after a single oral dose of HYD 20-
mg extended-release tablets. Because the magnitude of
the interaction with paroxetine was not known, a 20-
mg single dose of HYD was selected so that it could be
administered without the need for naltrexone block-
ade in healthy subjects.
The CYP3A4 pathway leading to norhydrocodone
and the CYP2D6 pathway leading to hydromorphone
are major and minor routes of hydrocodone metabo-
lism, respectively.6 In addition to CYP2D6 and
CYP3A4, CYP isoforms 2B6, 2C9, 2C19, and 2E1 are
minor contributors.7 As such, the concurrent admini-
stration of either a CYP2D6 or CYP3A4 inhibitor may
increase systemic exposure to hydrocodone.
CYP2D6 inhibition has been reported to alter the
disposition and response to certain medications. For
example, previous studies have shown that the inhib-
ition of the CYP2D6 pathway using paroxetine wasOctober 2015associated with a decreased metabolism of metha-
done,13 and with perphenazine, led to increased
plasma concentrations and central nervous system
effects.14 Furthermore, PK drug–drug interactions
have been reported with the use of paroxetine and
the CYP2D6 substrate metoprolol.15
Although hydromorphone is an active metabolite,
the systemic exposure of hydromorphone without
CYP2D6 inhibition is only up to 3% of parent
hydrocodone.5 This ﬁnding is consistent with those
from previously published reports.6 Consequently, the
inhibition of the minor CYP2D6-mediated pathway
was expected to result in a minimal increase in
systemic exposure to hydrocodone.
In the present study, the geometric mean ratios
([HYD with paroxetine]/[HYD without paroxetine])
of hydrocodone AUC and Cmax values were 105.9%
(90% CI, 97.7–114.6) and 106.0% (90% CI, 92.7–
121.2), respectively. The absence of a signiﬁcant
change in the systemic levels of hydrocodone in the
presence of paroxetine reafﬁrms that the CYP2D6
metabolism of hydrocodone to hydromorphone
is a minor pathway. The mean hydromorphone
AUC0–t and Cmax values were less with paroxetine
administration compared with placebo (0.64 vs
3.8 ng  h/mL and 0.06 vs 0.19 ng/mL, respectively),
whereas the median Tmax values were similar (18.0 vs
16.1 hours, respectively). The mean hydromorphone
AUC0–1 value could not be calculated. Single doses
of 20-mg HYD administered in the presence or
absence of paroxetine at steady state (20 mg once
daily for 12 days) were well tolerated. These results
are included in the HYD full prescribing
information.5
Although the oral analgesic potency of hydromor-
phone, compared with hydrocodone, is 2.5-fold,16 a
low systemic exposure (3%) of hydromorphone
would be expected to contribute minimally to the
analgesic activity of hydrocodone. Therefore,
CYP2D6 inhibition in a clinical setting is anticipated
to have a minimal effect on the pharmacodynamic
properties of hydrocodone.
Polymorphic variants of CYP2D6 are known to
affect the metabolism of many drugs and can thereby
inﬂuence drug disposition and therapeutic response.17
Approximately 7% of the white US population and
2% to 7% of the black US population are poor
metabolizers of CYP2D6 substrates.18 Relative to
extensive metabolizers, poor metabolizers exhibit2293
Table III. Geometric least squares (LS) mean* pharmacokinetic values of hydrocodone in plasma (full analysis
population).
Parameter
Geometric LS Mean
Ratio (%)
of Geometric
LS Means†
90% CI for
Ratio‡
Intrasubject
%CV
Hydrocodone
Bitartrate
20 mg þ Paroxetine
(n ¼ 23)
Hydrocodone
Bitartrate
20 mg þ Placebo
(n ¼ 24)
AUC0–t,
ng  h/mL
332.9 314.5 105.9 97.7–114.6 15.9
AUC0–1,
ng  h/mL
336.5 317.8 105.9 97.8–114.6 15.7
Cmax, ng/mL 16.1 15.2 106.0 92.7–121.2 27.1
*Analysis of variance. Natural logarithm (ln) parameter means were calculated by transforming the ln means back to the
linear scale (ie, geometric means).
†Ratio of test to reference parameter means for ln-transformed parameter (expressed as a percentage). Ln-transformed ratio
was transformed back to linear scale.
‡The 90% CI for ratio of test to reference parameter means (expressed as a percentage). Ln-transformed conﬁdence limits
were transformed back to linear scale.
Table IV. Tolerability of hydrocodone (per-protocol population).*
Type of AE
Hydrocodone Bitartrate 20 mg þ Paroxetine Hydrocodone Bitartrate 20 mg þ Placebo
Before
Administration of
Hydrocodone
Bitartrate
(n ¼ 24)
After
Administration of
Hydrocodone
Bitartrate
(n ¼ 23)
All
Patients
(N ¼ 24)
Before
Administration of
Hydrocodone
Bitartrate
(n ¼ 24)
After
Administration of
Hydrocodone
Bitartrate
(n ¼ 24)
All
Patients
(N ¼ 24)
Any AE 7 (29) 4 (17) 9 (38) 3 (13) 3 (13) 5 (21)
Treatment-
related AEs†
7 (29) 4 (17) 9 (38) 3 (13) 3 (13) 5 (21)
AEs occurring in 45% of subjects
Headache 4 (17) 1 (4) 4 (17) 0 1 (4) 1 (4)
Nausea 3 (13) 0 3 (13) 0 2 (8) 2 (8)
Asthenia 2 (8) 0 2 (8) 0 0 0
Diarrhea 2 (8) 0 2 (8) 0 0 0
AE ¼ adverse event.
*AEs are listed by Medical Dictionary for Regulatory Activities preferred terms as number of occurrences (%); all other data are
listed as number of subjects (%). None of the AEs was considered moderate or severe in intensity. No deaths, serious AEs, or
early discontinuations due to AEs were reported.
†Related to study medication ¼ unlikely, possibly, probably, or deﬁnitely related categories on the AE case-report form.
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administration of hydrocodone19; however, CYP2D6-
metabolizer status does not appear to affect the phar-
macodynamic response to hydrocodone.19 Even with the
abolishment of the CYP2D6 minor oxidative pathway
of metabolism by quinidine in poor CYP2D6 meta-
bolizers of hydrocodone, extensive as well as poor
metabolizers responded similarly to oral hydrocodone.
These data suggest only a small role of hydromorphone
in eliciting abuse-related responses to oral hydroco-
done.19 The apparent discrepancy between the in vitro
binding afﬁnity20 and in vivo equianalgesia16 μ-receptor
relative binding afﬁnity of hydromorphone relative to
hydrocodone most likely may be due to lesser bioavail-
ability (due to extensive ﬁrst-pass metabolism of
hydromorphone) and poor relative penetration of hy-
dromorphone into the central nervous system.CONCLUSION
In this population of 24 healthy subjects, the coad-
ministration of single-dose HYD with paroxetine at
steady state did not alter systemic exposure to hydro-
codone, suggesting that HYD can be coadministered
with CYP2D6 inhibitors at therapeutic doses, without
dosage modiﬁcation.ACKNOWLEDGMENTS
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